EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Outcomes and Reclassification Patterns in Inflammatory Bowel Disease Unclassified: A Multicenter Study Matched With Ulcerative Colitis From Spanish ENEIDA Registry

M González-Vivó iD, B Castro Senosiain, I Pérez-Martínez iD, J Barrio iD, P Vega Villaamil iD, B Caballol Oliva iD, V Pedrera Roman, M Piqueras Cano iD, F Rodríguez Moranta iD, M Iborra iD, M J Casanova iD, J P Gisbert iD und 11 weitere

Journal of Gastroenterology and Hepatology · 2026-11 · 41 (11) · 3413-3421

DOI: 10.1111/jgh.70745 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 21.09.2026. Verfasst von M González-Vivó und 22 weiteren Autor:innen. Beteiligte Einrichtung: Hospital de Viladecans, Viladecans, Spain. Hauptthemen laut MEDLINE: Registries, Colitis, Ulcerative, Inflammatory Bowel Diseases. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Biogen, Abbvie, Galapagos, Takeda, and Pfizer, Biogen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Around 10% of patients with inflammatory bowel disease do not fulfill the diagnostic criteria for Crohn's disease (CD) or ulcerative colitis (UC). These cases are labelled as inflammatory bowel disease unclassified (IBDU). The aim of the study was to compare therapeutic requirements in patients with IBDU and UC and to identify predictive factors of reclassification.

Methods

This was a multicenter retrospective cohort study based on the ENEIDA registry. Patients diagnosed with IBDU or indeterminate colitis between January 2010 and December 2016 were included. All cases were matched by sex, age at diagnosis, and disease extent with at least two UC patients from the same hospital. The Kaplan–Meier method was performed to assess diagnostic changes during follow‐up. Fine–Gray competing‐risks regression analysis identified predictive factors of reclassification.

Results

Two hundred and nine IBDU patients and 465 UC patients were included. After a median follow‐up of 90 months, no significant differences were observed in the use of immunomodulator (37.3% vs. 37%, p = 0.934) and advanced therapies (29.2% vs. 23.9%, p = 0.143) between IBDU and UC. No statistical differences were found in the surgical rates (5.7% vs. 4.7%, p = 0.579). Overall, 59 IBDU patients (28.2%) were reclassified (30 UC and 29 CD). Baseline extensive colitis was associated with a lower probability of subsequent reclassification to UC (SHR: 0.33; 95% CI: 0.12–0.91). No independent predictive factors for reclassification to CD were identified.

Conclusions

Therapeutic management of IBDU and UC patients tended to be similar. Two‐thirds of patients remained classified as IBDU.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RegistriesColitis, UlcerativeInflammatory Bowel DiseasesHumansFemaleMaleRetrospective StudiesSpainAdultMiddle AgedFollow-Up StudiesTreatment OutcomeTime FactorsCohort StudiesCrohn DiseaseImmunologic Factors

Stichwörter der Autor:innen

biological therapyclassificationinflammatory bowel diseasesulcerative colitis

Substanzen

Immunologic Factors

Autor:innen und Institutionen

  • Hospital de Viladecans, Viladecans, Spain.
  • Hospital del Mar Medical Research Institute (IMIM), Hospital del Mar, Barcelona, Spain.
  • Instituto de Investigación IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Instituto de Investigación Biosanitaria del Principado de Asturias (ISPA), Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Gerencia Regional de Salud de Castilla y León (SACYL), Hospital Universitario Río Hortega, Valladolid, Spain.
  • Complexo Hospitalario Universitario de Ourense, Ourense, Spain.

ORCID-Profile: M González-Vivó, I Pérez-Martínez, J Barrio, P Vega Villaamil, B Caballol Oliva, M Piqueras Cano, F Rodríguez Moranta, M Iborra, M J Casanova, J P Gisbert, C Tardillo Marin, L Ramos, M Urpi-Ferreruela, R H Lorente Poyatos, M Barreiro-de Acosta, O Belen Galipienso, L Bujanda, Y Zabana, F Murciano, E Domènech, L Márquez-Mosquera

Förderung

  • Biogen, Abbvie, Galapagos, Takeda, and Pfizer
  • Biogen

Zitieren

APA

González-Vivó, M., Castro Senosiain, B., Pérez-Martínez, I., Barrio, J., Vega Villaamil, P., Caballol Oliva, B., Pedrera Roman, V., Piqueras Cano, M., Rodríguez Moranta, F., Iborra, M., Casanova, M. J., Gisbert, J. P., Tardillo Marin, C., Ramos, L., Urpi-Ferreruela, M., Lorente Poyatos, R. H., Barreiro-de Acosta, M., Belen Galipienso, O., Bujanda, L., …, & Márquez-Mosquera, L. (2026). Outcomes and Reclassification Patterns in Inflammatory Bowel Disease Unclassified: A Multicenter Study Matched With Ulcerative Colitis From Spanish ENEIDA Registry. Journal of Gastroenterology and Hepatology, 41(11), 3413-3421. https://doi.org/10.1111/jgh.70745

Vancouver

González-Vivó M, Castro Senosiain B, Pérez-Martínez I, Barrio J, Vega Villaamil P, Caballol Oliva B, et al. Outcomes and Reclassification Patterns in Inflammatory Bowel Disease Unclassified: A Multicenter Study Matched With Ulcerative Colitis From Spanish ENEIDA Registry. Journal of Gastroenterology and Hepatology. 2026;41(11):3413-3421. doi:10.1111/jgh.70745

BibTeX
@article{GonzlezViv2026,
  author = {González-Vivó, M and Castro Senosiain, B and Pérez-Martínez, I and Barrio, J and Vega Villaamil, P and Caballol Oliva, B and Pedrera Roman, V and Piqueras Cano, M and Rodríguez Moranta, F and Iborra, M and Casanova, M J and Gisbert, J P and Tardillo Marin, C and Ramos, L and Urpi-Ferreruela, M and Lorente Poyatos, R H and Barreiro-de Acosta, M and Belen Galipienso, O and Bujanda, L and Zabana, Y and Murciano, F and Domènech, E and Márquez-Mosquera, L},
  title = {Outcomes and Reclassification Patterns in Inflammatory Bowel Disease Unclassified: A Multicenter Study Matched With Ulcerative Colitis From Spanish ENEIDA Registry},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  volume = {41},
  number = {11},
  pages = {3413--3421},
  doi = {10.1111/jgh.70745}
}
Kostenlos starten →